CD8A and infection: Its efficacy is largely unaffected by the amino acid substitutions occurring in emerging viral variants [2], and the infection with low pathogenic coronaviruses can generate an effective anti-SARS-CoV-2 CD8+ T-cell immunity due to the cross-reactivity of virus-specific CD8+ T-cells [3].